Clinical trials: Depressions, Refractory
Treatment Resistant Depression, Visual Perceptual Weakness
Positron Emission Tomography in Transcranial Magnetic Stimulation Intervention for Treatment-resistant Depression
Major depressive disorder (MDD) exhibit reduced visual motor perception, which affects prognosis. Metabolic substance changes and abnormal neural activity in the middle temporal visual area (MT) mediate this perceptual…
- Trial name
- NCT06044324
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Treatment Resistant Depression, Major Depressive Disorder (MDD)
Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression
The goal of this clinical trial is to see if combining ketamine with behavioral activation (BA) therapy to treat moderate to severe treatment-resistant depression improves depressive symptoms and general functioning more than…
- Trial name
- NCT07801703
- Testing
- Ketamine (0.5 mg/kg), Behavioural Activation Therapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- The Royal's Institute of Mental Health Research
Major Depressive Disorder
Comparison of Anodal Transcranial Direct Current Stimulation (t-DCS) and Sham Stimulation in Patients With Treatment-resistant Depression
Major depressive disorder (MDD) is a significant public health problem. Existing treatment modalities are not always sufficient to alleviate this disorder. Treatment refractoriness is a common clinical problem.
- Trial name
- NCT02141776
- Testing
- Transcranial direct current stimulation (t-DCS)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Florida
Treatment Resistant Depression, Major Depressive Disorder
Clinical Study of GH001 in Depression
The aim of the study is to investigate the safety of GH001 (containing 5-methoxy-dimethyltryptamine; 5-MeO-DMT), and to investigate its effects on severity of depressive symptoms, and its dose-related psychoactive effects in…
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Depression
- Trial name
- NCT04698603
- Testing
- 5 Methoxy N,N Dimethyltryptamine
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- GH Research Ireland Limited
Depressive Disorder, Treatment-Resistant, Memory Deficits
SAINT® Therapy for Memory Problems in Older Adults With Treatment-Resistant Depression
The goal of this clinical trial is to learn whether Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT®), a type of transcranial magnetic stimulation (TMS), is safe and may improve memory and thinking in adults aged…
- Trial name
- NCT07876908
- Testing
- Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT®) with the Magnus Neuromodulation System
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- BrainHealth Solutions, Inc.
Treatment Resistant Depression (TRD)
Treatment Resistant Depression and Vagus Nerve Stimulation
Depression is a common illness, affecting 17% of the population over the course of a lifetime. A third of depressions relapses and progresses to recurrence and resistance to treatments.
- Trial name
- DepVNS (NCT05952674)
- Testing
- Vagus Nerve Stimulation (VNS), Best Medical Treatment
- Where
- 24 sites in France
- Volunteers
- 166 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Major Depressive Disorder, Treatment Resistant Depression
An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients
The TARGET study is an active-controlled evaluation of AXS-05 compared to bupropion in patients with treatment-resistant major depressive disorder (MDD) who are adherent to study drug.
- Trial name
- TARGET (NCT04971291)
- Testing
- AXS-05, Bupropion SR
- Where
- United States
- Volunteers
- 312 people
- Sponsor
- Axsome Therapeutics, Inc.
Treatment Resistant Depression
Interpersonal Psychotherapy for Treatment Resistant Depression
The purpose of this study is to determine whether combination of antidepressant drugs plus interpersonal psychotherapy is superior to antidepressant drugs alone in treatment resistant depression.
- Trial name
- NCT01896349
- Testing
- IPT+ antidepressant drugs, fluoxetine, sertraline
- Where
- Brazil
- Volunteers
- 74 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Major Depressive Disorder
Ketamine in Adolescents With Treatment-Resistant Depression
This study will test the use of ketamine for treatment of depression in adolescents that have not responded to other treatments. We will also examine neurobiological mechanisms of treatment.
- Trial name
- NCT02078817
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Minnesota
Major Depressive Disorder, Treatment Resistant Depression
Low-Intensity Focused Ultrasound for Treatment-Resistant Depression
The Investigators are proposing to demonstrate safety and efficacy of LIFUP for treatment resistant major depressive disorder in a ten-patient pilot study.
- Trial name
- NCT06013384
- Testing
- Low-Intensity Focused Ultrasound Pulsation
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Medical University of South Carolina
Adolescent Depression
Lamotrigine in Treatment Resistant Depression in Adolescents
The primary hypothesis of this study is that in fluoxetine (Prozac)-resistant adolescents with Major Depressive Disorder (MDD), Lamotrigine plus fluoxetine will be safe and as effective as sertraline (Zoloft).
- Trial name
- NCT00284791
- Testing
- Lamotrigine (drug), Fluoxetine (drug), sertraline (drug)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- MaineHealth
Major Depression
TBS Over DLPFC in Elderly Refractory Depression
The study aim to examine the effect of Thea-burst stimulation over bilateral dorsolateral prefrontal cortex (DLPFC) among patients with LLD on mood condition and relevant biomarkers.
- Trial name
- NCT04872465
- Testing
- TBS
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Treatment-Resistant Depression
Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychological support in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects.
- Trial name
- PSI-TNT (NCT07211438)
- Testing
- Psilocybin
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Centre for Addiction and Mental Health
Treatment Resistant Depression, Major Depressive Disorder
ECT vs. Esketamine
Treatment-resistant depression (TRD) is a common cause of disability and one of the most common psychiatric disorders worldwide. Electroconvulsive therapy (ECT) is currently the most effective treatment for TRD.
- Trial name
- ETES (NCT04924257)
- Testing
- Esketamine nasal spray, Electroconvulsive therapy
- Where
- Austria
- Sponsor
- Medical University Innsbruck
MDD, Major Depressive Disorder
pBFS Guided rTMS Therapy Over Different Targets for Treatment-Resistant Depression
To explore the effectiveness and safety of rTMS intervention with different targets in the left prefrontal cortex defined using the pBFS method, in adult patients with moderate and severe depressive disorder.
- Conditions
- MDD, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- NCT05976022
- Testing
- active rTMS
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Changping Laboratory
Resistant Depression, Treatment
TReAtment With CombinedExercise in Patients With Resistant Major Depression
Major depressive disorder is one of the most prevalent and disabling mental disorders worldwide. Forty percent of people with major depressive disorder are in moderate remission, with the remainder meeting the criteria for…
- Trial name
- TRACE-RMD (NCT05136027)
- Testing
- Combined training
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- University of the Basque Country (UPV/EHU)
Treatment-resistant Depression (TRD)
Esketamine With or Without Integration Therapy for Treatment-Resistant Depression
This study will explore the effects of esketamine (Spravato®), an FDA-approved nasal spray, on adults diagnosed with treatment-resistant depression (TRD).
- Trial name
- KIND-PR (NCT07369102)
- Testing
- Esketamine hydrochloride (intranasal), Integration Therapy
- Where
- 2 sites in Puerto Rico
- Volunteers
- 20 people
- Sponsor
- University of Puerto Rico
Treatment-Resistant Depression
Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression
Approximately one third of individuals with Major Depressive Disorder (MDD) are considered treatment-resistant, subject to severe disability and risk of suicide, and exhibit symptoms anchored in abnormalities of Research Domain…
- Trial name
- LIFU CANVAS (NCT07166289)
- Testing
- Low-intensity focused ultrasound
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Laureate Institute for Brain Research, Inc.
Treatment-Resistant Depression
pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Depression
We aim to evaluate the safety and efficacy of pBFS-guided high-dose rTMS therapy with short inter-session interval for patients with treatment-resistant depression
- Trial name
- NCT05842291
- Testing
- Active rTMS with short inter-session interval, Active rTMS with long inter-session interval
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changping Laboratory
Treatment Resistant Depression
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression (SAINT-TRD)
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression.
- Trial name
- aTBS (NCT03068715)
- Testing
- Active TBS-DLPFC, Open label TBS-DLPFC
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University